

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 October 2022 (06.10.2022)



(10) International Publication Number
WO 2022/208356 A1

(51) International Patent Classification:

C07D 417/14 (2006.01) A61K 31/439 (2006.01)
A61K 31/04 (2006.01) A61K 31/454 (2006.01)
A61K 31/43 (2006.01) A61K 31/4985 (2006.01)
A61K 31/69 (2006.01) C07D 471/04 (2006.01)
A61K 31/424 (2006.01) C07D 471/08 (2006.01)
A61K 31/427 (2006.01) C07D 471/18 (2006.01)
A61K 31/428 (2006.01) C07D 487/04 (2006.01)
A61K 31/431 (2006.01) C07D 499/86 (2006.01)
A61K 31/433 (2006.01) C07D 503/18 (2006.01)
A61K 31/437 (2006.01) C07F 5/02 (2006.01)

(21) International Application Number:

PCT/IB2022/052900

(22) International Filing Date:

29 March 2022 (29.03.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/168,406 31 March 2021 (31.03.2021) US

(71) Applicant: **FEDORA PHARMACEUTICALS INC.**
[CA/CA]; 11629 105 Avenue NW, Edmonton, Alberta T5H
0L9 (CA).

(72) Inventors: **JANKOWSKA, Renata**; c/o Fedora Pharma-
ceuticals Inc., 11629 105 Avenue NW, Edmonton, Alberta
T5H 0L9 (CA). **SALAMA, Sameeh M.**; c/o Fedora Pharma-
ceuticals Inc., 11629 105 Avenue NW, Edmonton, Al-
berta T5H 0L9 (CA). **MAITI, Samarendra N.**; c/o Fedora
Pharmaceuticals Inc., 11629 105 Avenue NW, Edmonton,
Alberta T5H 0L9 (CA).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,


NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: LACTIVICIN COMPOUNDS, THEIR PREPARATION AND USE AS ANTIBACTERIAL AGENTS



(57) Abstract: Lactivicin compounds of formula (I) and pharmaceutically acceptable salts of the compounds of formula (I) are provided, wherein the compounds comprise antibiotics suitable for use either alone or in combination with P-lactamase inhibitors and/or other antibiotics (including P-lactam and non-P-lactam antibiotics) in the treatment or prevention of bacterial infections.

WO 2022/208356 A1